secwatch / observer

8-K filed June 1, 2026, 8:01 AM ET ticker JSPR CIK 0001788028

other material confidence high sentiment neutral materiality 0.85

Jasper Therapeutics initiates strategic review including potential sale or wind-down

Jasper Therapeutics, Inc.

Board of Directors initiates comprehensive review of strategic alternatives to maximize shareholder value.
Options include sale of assets/licensing, collaboration, merger, business combination, or orderly wind-down.
Company to continue evaluating cost-saving measures to preserve cash during the process.
No defined timeline for the review; no assurance any transaction will be consummated.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-063157
form_type: 8-K
ticker: JSPR
cik: 0001788028
company_name: Jasper Therapeutics, Inc.
filed_at: 2026-06-01T12:01:20+00:00
discovered_at: 2026-06-01T12:05:00.309639+00:00
generated_at: 2026-06-01T12:06:10.718204+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-063157
json_url: https://secwatch.observer/filing/0001213900-26-063157.json
markdown_url: https://secwatch.observer/filing/0001213900-26-063157.md
text_url: https://secwatch.observer/filing/0001213900-26-063157.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/0001213900-26-063157-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/ea0292909-8k_jasper.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

LIXT

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC. June 1, 2026, 8:55 AM ET other_material Items 5.02, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TTRX

Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs

Turn Therapeutics Inc. June 1, 2026, 8:45 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SOC

Sable Offshore reports first reserve post-restart: 90.5 MMbbl proved developed oil, PV10 $1.47B

Sable Offshore Corp. June 1, 2026, 6:38 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MNTS

Momentus raises $25M via private placement of common stock at $8.50/share

Momentus Inc. May 29, 2026, 4:51 PM ET other_material Items 1.01, 3.02, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-26-063157

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.